Management of Agitation in ACS Patients
In patients with acute coronary syndrome, agitation should be managed with opiates as the first-line strategy, combined with delirium assessment and management, while avoiding antipsychotics when possible due to arrhythmia risk. 1
Algorithmic Approach to Agitation Management
Step 1: Assess and Treat Pain First
Before addressing agitation with sedatives, assess and treat pain using validated pain scales. Pain itself is a major driver of agitation in ACS patients, and treating the underlying pain may resolve agitation without additional sedation 2. ACS patients commonly experience moderate to severe pain in the chest, arms, back, shoulders, and jaw 3.
Step 2: Opiate-Based Strategy
Opiates (morphine, fentanyl) are the preferred agents for managing agitation in ACS patients because they:
- Provide analgesia for ischemic pain
- Have beneficial effects on the ischemic heart (may increase coronary blood flow and decrease oxygen consumption)
- Exert anti-arrhythmic effects via kappa receptor stimulation and sympatholytic properties
- Increase the electrical fibrillation threshold of the ventricle 1
Critical caveat: Allow adequate time for antiplatelet loading (aspirin, P2Y12 inhibitors) before initiating opiates to avoid deleterious pharmacodynamic interactions 1.
Step 3: Assess for Delirium
Use validated tools (CAM-ICU) to assess for delirium, as delirium management is part of the core strategy alongside opiates 1.
Step 4: Adjunctive Sedation (If Needed)
If additional sedation is required beyond opiates:
For patients WITHOUT severe LV dysfunction or large ischemic areas:
- Propofol may be used cautiously
- Propofol decreases LV myocardial workload with matched reductions in oxygen consumption
- Provides ischemia-reperfusion protection
- Has potential anti-arrhythmic effects 1
For patients WITH severe LV dysfunction, large ischemic areas, or acute heart failure:
- Benzodiazepines are the safer cardiovascular agent
- They may increase coronary blood flow and decrease oxygen consumption in the ischemic heart
- Do not promote myocardial ischemia or interfere with coronary autoregulation 1
Step 5: Avoid Antipsychotics in High-Risk Situations
Antipsychotics should be avoided when there is high risk for ventricular arrhythmias because they:
- Delay myocardial repolarization
- Increase risk for torsade de pointes and sudden cardiac death
- Are particularly dangerous in patients with prolonged QTc (>500 ms), electrolyte abnormalities, or concurrent QTc-prolonging medications 1
If an antipsychotic is absolutely necessary, haloperidol has less QTc-prolonging effect than ziprasidone, though it paradoxically causes more torsade de pointes, especially when given intravenously. Aripiprazole has not been associated with QTc prolongation 1.
Key Clinical Pitfalls
Don't sedate before treating pain - This violates the analgesia-first principle and may worsen outcomes 2
Don't forget antiplatelet loading timing - Opiates can interfere with antiplatelet drug absorption and effect 1
Don't use deep sedation routinely - Light sedation is preferred in critically ill patients when sedation is needed 2
Don't overlook anxiety assessment - While pain is typically well-assessed in ACS, anxiety is often not routinely assessed or treated, yet contributes significantly to agitation 3
Evidence Quality Considerations
The 2019 European Heart Journal guideline 1 provides the most specific and authoritative guidance for this population, acknowledging that "there is a lack of data to guide an evidence-based sedation protocol for those patients with an ischemic heart." The recommendations are therefore based on pharmacologic principles and extrapolation from related conditions. The 2018 Critical Care Medicine guidelines 2 provide strong support for the analgesia-first, protocol-based approach but are not ACS-specific.